Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2010 1
2012 2
2014 1
2015 2
2016 3
2017 7
2018 8
2019 7
2020 13
2021 16
2022 6
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

63 results

Results by year

Filters applied: . Clear all
Page 1
Hepatotoxicity in patients with non-small cell lung cancer treated with sotorasib after prior immunotherapy: a comprehensive clinical and pharmacokinetic analysis.
Ernst SM, Hofman MM, van der Horst TE, Paats MS, Heijboer FWJ, Aerts JGJV, Dumoulin DW, Cornelissen R, von der Thüsen JH, de Bruijn P, Hoop EO, Mathijssen RHJ, Koolen SLW, Dingemans AC. Ernst SM, et al. Among authors: cornelissen r. EBioMedicine. 2024 Apr;102:105074. doi: 10.1016/j.ebiom.2024.105074. Epub 2024 Mar 19. EBioMedicine. 2024. PMID: 38507877 Free PMC article.
Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.
Tsuboi M, Herbst RS, John T, Kato T, Majem M, Grohé C, Wang J, Goldman JW, Lu S, Su WC, de Marinis F, Shepherd FA, Lee KH, Le NT, Dechaphunkul A, Kowalski D, Poole L, Bolanos A, Rukazenkov Y, Wu YL; ADAURA Investigators. Tsuboi M, et al. N Engl J Med. 2023 Jul 13;389(2):137-147. doi: 10.1056/NEJMoa2304594. Epub 2023 Jun 4. N Engl J Med. 2023. PMID: 37272535 Clinical Trial.
Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4).
Cornelissen R, Prelaj A, Sun S, Baik C, Wollner M, Haura EB, Mamdani H, Riess JW, Cappuzzo F, Garassino MC, Heymach JV, Socinski MA, Leu SY, Bhat G, Lebel F, Le X; ZENITH20-4 Investigators. Cornelissen R, et al. J Thorac Oncol. 2023 Aug;18(8):1031-1041. doi: 10.1016/j.jtho.2023.03.016. Epub 2023 Mar 21. J Thorac Oncol. 2023. PMID: 36958688 Clinical Trial.
Multi-source data approach for personalized outcome prediction in lung cancer screening: update from the NELSON trial.
Sidorenkov G, Stadhouders R, Jacobs C, Mohamed Hoesein FAA, Gietema HA, Nackaerts K, Saghir Z, Heuvelmans MA, Donker HC, Aerts JG, Vermeulen R, Uitterlinden A, Lenters V, van Rooij J, Schaefer-Prokop C, Groen HJM, de Jong PA, Cornelissen R, Prokop M, de Bock GH, Vliegenthart R. Sidorenkov G, et al. Among authors: cornelissen r. Eur J Epidemiol. 2023 Apr;38(4):445-454. doi: 10.1007/s10654-023-00975-9. Epub 2023 Mar 21. Eur J Epidemiol. 2023. PMID: 36943671 Free PMC article. Clinical Trial.
Lurbinectedin shows clinical activity and immune-modulatory functions in patients with pre-treated small cell lung cancer and malignant pleural mesothelioma.
Dumoulin DW, Cantini L, Cornelissen R, Vink M, Klaase L, Slooff K, Tebayna N, Mankor JM, Baart SJ, Hendriks R, Dingemans AC, Willemsen M, Aerts JGJV. Dumoulin DW, et al. Among authors: cornelissen r. Eur J Cancer. 2022 Sep;172:357-366. doi: 10.1016/j.ejca.2022.06.020. Epub 2022 Jul 11. Eur J Cancer. 2022. PMID: 35834843 Free article.
Implementing Lung Cancer Screening in Europe: Taking a Systems Approach.
Wait S, Alvarez-Rosete A, Osama T, Bancroft D, Cornelissen R, Marušić A, Garrido P, Adamek M, van Meerbeeck J, Snoeckx A, Leleu O, Hult EH, Couraud S, Baldwin DR. Wait S, et al. Among authors: cornelissen r. JTO Clin Res Rep. 2022 Apr 22;3(5):100329. doi: 10.1016/j.jtocrr.2022.100329. eCollection 2022 May. JTO Clin Res Rep. 2022. PMID: 35601926 Free PMC article. Review.
63 results